These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26829221)

  • 1. Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
    Ouyang M; White EE; Ren H; Guo Q; Zhang I; Gao H; Yanyan S; Chen X; Weng Y; Da Fonseca A; Shah S; Manuel ER; Zhang L; Vonderfecht SL; Alizadeh D; Berlin JM; Badie B
    PLoS One; 2016; 11(2):e0148139. PubMed ID: 26829221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory CpG on Carbon Nanotubes Selectively Inhibits Migration of Brain Tumor Cells.
    Alizadeh D; White EE; Sanchez TC; Liu S; Zhang L; Badie B; Berlin JM
    Bioconjug Chem; 2018 May; 29(5):1659-1668. PubMed ID: 29526082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
    Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
    McConville P; Hambardzumyan D; Moody JB; Leopold WR; Kreger AR; Woolliscroft MJ; Rehemtulla A; Ross BD; Holland EC
    Clin Cancer Res; 2007 May; 13(10):2897-904. PubMed ID: 17504989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
    Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
    Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy.
    Zhou S; Hashida Y; Kawakami S; Mihara J; Umeyama T; Imahori H; Murakami T; Yamashita F; Hashida M
    Int J Pharm; 2014 Aug; 471(1-2):214-23. PubMed ID: 24861942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
    Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
    Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
    Zhu X; Fujita M; Snyder LA; Okada H
    J Neurooncol; 2011 Aug; 104(1):83-92. PubMed ID: 21116835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Asparaginase
    Sanghez V; Chen M; Li S; Chou TF; Iacovino M; Lin HJ; Lasky JL; Panosyan EH
    Anticancer Res; 2018 May; 38(5):2627-2634. PubMed ID: 29715082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
    Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
    Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity.
    Zhao D; Alizadeh D; Zhang L; Liu W; Farrukh O; Manuel E; Diamond DJ; Badie B
    Clin Cancer Res; 2011 Feb; 17(4):771-82. PubMed ID: 21088258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting enhances the response of glioma to chemo- and radiotherapy.
    Safdie F; Brandhorst S; Wei M; Wang W; Lee C; Hwang S; Conti PS; Chen TC; Longo VD
    PLoS One; 2012; 7(9):e44603. PubMed ID: 22984531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
    Zhang R; Saito R; Shibahara I; Sugiyama S; Kanamori M; Sonoda Y; Tominaga T
    J Neurooncol; 2016 Jan; 126(2):235-42. PubMed ID: 26530267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
    Ziegler DS; Keating J; Kesari S; Fast EM; Zawel L; Ramakrishna N; Barnes J; Kieran MW; Veldhuijzen van Zanten SE; Kung AL
    Neuro Oncol; 2011 Aug; 13(8):820-9. PubMed ID: 21724651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.